Pharmaceuticals · THE WOODLANDS, TX, United States
$2.28
-0.13% (-$0.00)2026-07-09
Smart-Money SignalNeutral · 48/100— Insider open-market flow is flat over 90 days
Revenue$21.1M
Net Income-$1.0M
EPS$0.00
Market Cap$968.5M
Price Performance
Historical data including institutional events
Company Profile
M
Mike Exton
CEO & Executive Director
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
